Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Almici C
Bone Marrow Transplant. 16(1):95-101.
Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Dotti G
Haematologica. 80(2):142-5.
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Carlo-Stella C
Bone Marrow Transplant. 14(3):425-32.
Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients.
Carlo-Stella C
Blood. 83(5):1373-80.
Acquired cyclic thrombocytopenia-thrombocytosis with periodic defect of platelet function.
Balduini CL
Br J Haematol. 85(4):718-22.
Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Carlo-Stella C
Blood. 80(9):2412-8.
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C
Exp Hematol. 20(3):328-33.
Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia.
Bergamaschi G
Leukemia. 5(10):886-91.
In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte–macrophage colony-stimulating factor.
Carlo-Stella C
Bone Marrow Transplant. 8(4):265-73.
Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells.
Ottmann OG
Exp Hematol. 19(8):773-8.